Wall Street Zen Downgrades Integra LifeSciences (NASDAQ:IART) to Buy

Integra LifeSciences (NASDAQ:IART) was downgraded by stock analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research report issued on Saturday.

Several other equities research analysts have also recently commented on the stock. Truist Financial lifted their price target on shares of Integra LifeSciences from $14.00 to $19.00 and gave the stock a “hold” rating in a research report on Thursday. Citigroup restated a “neutral” rating and issued a $19.00 price objective (up from $16.00) on shares of Integra LifeSciences in a report on Wednesday, July 8th. Weiss Ratings raised shares of Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, May 13th. BMO Capital Markets assumed coverage on shares of Integra LifeSciences in a report on Wednesday, July 8th. They set a “market perform” rating and a $19.00 target price for the company. Finally, Wells Fargo & Company upped their target price on shares of Integra LifeSciences from $12.00 to $15.00 and gave the company an “equal weight” rating in a research report on Wednesday, May 6th. One equities research analyst has rated the stock with a Buy rating, four have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Reduce” and a consensus price target of $18.33.

Integra LifeSciences Price Performance

Integra LifeSciences stock opened at $19.25 on Friday. The business’s 50-day simple moving average is $16.91 and its 200 day simple moving average is $13.08. The company has a quick ratio of 1.95, a current ratio of 3.38 and a debt-to-equity ratio of 1.75. The stock has a market cap of $1.50 billion, a price-to-earnings ratio of -2.98, a P/E/G ratio of 1.37 and a beta of 1.22. Integra LifeSciences has a 12-month low of $8.70 and a 12-month high of $20.26.

Integra LifeSciences (NASDAQ:IART) last announced its quarterly earnings data on Tuesday, May 5th. The life sciences company reported $0.54 earnings per share for the quarter, topping the consensus estimate of $0.41 by $0.13. Integra LifeSciences had a positive return on equity of 17.42% and a negative net margin of 30.15%.The firm had revenue of $391.92 million during the quarter, compared to analysts’ expectations of $381.81 million. During the same period in the previous year, the business posted $0.41 EPS. The company’s quarterly revenue was up 2.4% compared to the same quarter last year. Integra LifeSciences has set its FY 2026 guidance at 2.400-2.500 EPS and its Q2 2026 guidance at 0.440-0.520 EPS. As a group, research analysts anticipate that Integra LifeSciences will post 2.45 earnings per share for the current year.

Institutional Trading of Integra LifeSciences

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Osaic Holdings Inc. boosted its position in shares of Integra LifeSciences by 36.6% during the second quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company’s stock worth $51,000 after purchasing an additional 1,104 shares in the last quarter. State of Tennessee Department of Treasury grew its holdings in shares of Integra LifeSciences by 7.9% in the 4th quarter. State of Tennessee Department of Treasury now owns 26,745 shares of the life sciences company’s stock valued at $332,000 after buying an additional 1,964 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Integra LifeSciences by 5.1% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,441 shares of the life sciences company’s stock valued at $889,000 after buying an additional 1,975 shares in the last quarter. Capital Fund Management S.A. increased its position in shares of Integra LifeSciences by 5.7% in the 3rd quarter. Capital Fund Management S.A. now owns 37,322 shares of the life sciences company’s stock valued at $535,000 after buying an additional 1,997 shares in the last quarter. Finally, Global Retirement Partners LLC acquired a new stake in Integra LifeSciences during the 4th quarter worth $25,000. 84.78% of the stock is owned by institutional investors.

Integra LifeSciences Company Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.